Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Meltem Culha"'
Autor:
Ayca Yildiz Pekoz, Ozlem Akbal Dagistan, Hanan Fael, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Muge Serhatli, Gamze Cakirca, Saban Tekin, Leyla Semiha Sen, Mustafa Sevim, Lutfiye Mulazimoglu Durmusoglu, Berrak C. Yegen
Publikováno v:
Drug Delivery, Vol 29, Iss 1, Pp 2846-2854 (2022)
Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2. However, poor accumulation of favipiravir in lung tissue following oral administration has requi
Externí odkaz:
https://doaj.org/article/bdfea95241b44c239c118b5475ad3aa0
Autor:
Ozlem Akbal-Dagistan, Mustafa Sevim, Leyla Semiha Sen, Nur Sena Basarir, Meltem Culha, Aybige Erturk, Hanan Fael, Engin Kaptan, Serap Sancar, Lutfiye Mulazimoglu Durmusoglu, Berrak C. Yegen, Ayca Yildiz-Pekoz
Publikováno v:
Pharmaceutics, Vol 14, Iss 11, p 2375 (2022)
Favipiravir displays a rapid viral clearance, a high recovery rate and broad therapeutic safety; however, its oral administration was associated with systemic side effects in susceptible patients. Considering that the pulmonary route could provide a
Externí odkaz:
https://doaj.org/article/a405212c83bd41d2b88449c959d06126
Autor:
Mustafa Erelel, Mert Kaskal, Ozlem Akbal-Dagistan, Halim Issever, Ahmet Serhan Dagistanli, Hilal Balkanci, Merve Sinem Oguz, Aygun Qarayeva, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Ali Yagiz Uresin, Ahmet Ogul Araman, Alpay Medetalibeyoglu, Tufan Tukek, Mustafa Oral Oncul, Ayca Yildiz-Pekoz
Publikováno v:
Pharmaceutics, Vol 13, Iss 11, p 1768 (2021)
In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was adm
Externí odkaz:
https://doaj.org/article/19984ebfb6c54daa9d40a18bd3016123
Autor:
Gokben Sahin, Ozlem Akbal-Dagistan, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Serap Sancar, Ayca Yildiz-Pekoz
Coronavirus Disease 2019 (COVID-19) pandemic has been on the agenda of humanity for more than 2 years. In the meantime, the pandemic has caused economic shutdowns, halt of daily lives and global mobility, overcrowding of the healthcare systems, panic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a16bdaad8bbb5e5b57517add0c1c8f7
https://hdl.handle.net/20.500.12713/2912
https://hdl.handle.net/20.500.12713/2912
Autor:
Halim Issever, Ahmet Serhan Dagistanli, Mustafa Erelel, Alpay Medetalibeyoglu, Nur Sena Basarir, Hilal Balkanci, Tufan Tükek, Ayca Yildiz-Pekoz, Aybige Erturk, Mustafa Oral Öncül, Merve Sinem Oguz, Mert Kaskal, Aygun Qarayeva, Ahmet Araman, Ali Yağız Üresin, Gokben Sahin, Ozlem Akbal-Dagistan, Meltem Culha
Publikováno v:
Pharmaceutics
Volume 13
Issue 11
Pharmaceutics, Vol 13, Iss 1768, p 1768 (2021)
Volume 13
Issue 11
Pharmaceutics, Vol 13, Iss 1768, p 1768 (2021)
In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was adm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb341af61ca44d3fcdde579b17139693
http://europepmc.org/articles/PMC8618458
http://europepmc.org/articles/PMC8618458